

*

(35-34) 3 6 50 (7)
) () 12 (1)
) ()
 .(2

/
 .(α<0.05)

.(2008)

:

(Smith, 2005; Darren

Tc 0.6 .and Scott, 2006)

Darren and %10

%2 .(Scott.2006)

(Lawrence et al., (30)

1996; Marino, 2002; Gabrielle et al., 2005; Susan, 2005;

Darren and Scott, 2006; Marc et al., 2006; Sandra and

Winfried, 2007)

(22-20)

(10-5)

.(Susan, 2005) (29-24)

(Gabrielle (38.5) /

(Lawrence et al., 2005)

et al., 1996; Susan et al., 2006)

.(Nag et al., 1998; Susan, 2005)

"Hyperthermia"

Hypothalamus

Thermoreceptors

()

"Body core temperature

(Duffield et

al.2003)

(Tc)"

() /

(Marino, 2002; Bodil and Lars, 2003; Gabrielle et al., 2005;

.2008/6/22

2008/1/17

*

/

(Marc et al., 2006; (2008 30 . (Marc et al., 2006) Sandra and Winfried, 2007) (10-8) 200-100 (Rushall and Pyke.1990) 15 15 300-150 (Lawrence et "Hyponatraemia" Muscular weakness, al., 1996) dizziness, headache, hypotension, tachycardia, mental .(Tortora and Derickson, 2006) confusion, stupor and coma .(Eran et al., 2004) (Lawrence et al., 1996; Darren and Scott, 2006) (Stocks et al.2004) / () / Marino.2002;Marc et (al.2006) (Susan et al., 2006) ("Cool") () (Marc et al.2006) (Maw et al (1998) 7 .(Marc et al.2006;Sandra and Winfried.2007) 50] : 3 / (°36.2) [(65-70% HR_{max}) .(°22) (°14.4) / Plasma volume %2 " TBW ")

| | | | | |
|---------------------|-------------------------|------------------------|----------------------|--------------------------|
| (5) | 12 | | Nag et al.(1998) | (5-0) |
| | (14) | | (36 33) | 4 |
| .(14) | () | |] : 3 / | .(26) |
| Bailey et al.(2007) | | | [| / |
| 20 | "DOMS" | | | / |
| 6 | 90 | VO _{2max} %75 | Stocks et al.(2004) | |
| 15 | "Blocks" | | | |
| [| 15×11 | | 8 | (ICF and ECF) |
| (10) | | |] : / | |
| (10) | 10 | 4 | (18) | |
| | | 60 | - | - |
| | Myoglobin | | [| (33) |
| | | | ICF | |
| | | | Aldosterone | |
| Plasma | Creatine kinase(CK/CPK) | | | |
| | (Haematocrit |) volume | Hiroshi et al.(2005) | |
| Sandra and Winfried | | | 9 | |
| (5-0) | (2007) | | .(32) | |
| / | 20 | 30 |] : 4 / | |
| : | 3/ | .(32-30) | 60 | - |
| / 1 | / 9 | | | - VO _{2max} %60 |
| [| 5 | -0) | [| VO _{2max} %80 |
| 20 | (5-0) | | | (5 |
| 20 | HR _{max} %70 | 1) | | |
| .(22 -20) | 20 | | | (16-14 / |
| / | | | | / |
| - | | | | / |
| | 3 - | | Susan et al.(2006) | |
| | | | () *(WBGT 27) | |
| | | | 15 | |
| 60 | (5) | |] : 3/ | |
| 10 (10) | | 30 | - | 90 |
| .() | | [2 | - | |

WBGT: Wet-bulb globe temperature.

"Blind-design"
 Cold "] : 10 16-14
 "Cold "water immersion (CWI) .
 ["Control trial (C)" water intake (W)"
 7
 -34) / "Treadmill"
 (%47-45) (35 .
 (30)
 (Susan.2005) 6
 Beijing-2008 22±0.1)
 Marc et al. 2006; Sandra and) 30 169±0.08 58.6±1
 (Winfried, 2007 10±0.0 2±0.08
 18) (/ 59.6±0.52
 -49) (26 -25) (.
 12 .(% 52 .
 (16-15)
 160
 48 .() : .1
 : .2
 "Physiological responses"
) . - Oral temperature (To) •
 () . - Heart rate (HR) •
 -Haematocrit (Hct) •
 () .
 (10) 500) . - Plasma volume (PV) •
 (250 250) (.
 "Euhydration") . - Aldosterone hormone •
 .(Hiroshi et al. 2005) (.
) . - Urine specific gravity (USG) •
 (.
) / .
 "Running/endurance time" (

80 - (10)
 .(80) / "Circadian cadence"
 (I) / 3

(10) () 50
 .(26-25) 20 ()
 400) / 14 Treadmill
 / 6 / 8 5
 (40,45 35 30 25 20) 2.5 / 1
) 70 20 (/ 14
 66 (20/ () 30
 / 12 (18)
 (C) / (16-15)
)
 "anterior superior iliac spine"
 ()
 HR 6)
 / (and To

! / 8 Treadmill
) "Volitional fatigue"
 (Marino, 2002) / 1 / 8
 (5
 / 8

(Lawrence et al., 1996; Darren and Sandra and
 .Scott, 2006) (Winfried.2007)

-
 1 -Collapse
 12
 12
 (W) /

160 (12)

| (35-34) | (26-25) 18/ | (35-34) |
|----------|--------------|----------|
| | 12 | 50 |
| | 6 | |

(Thermometer-A,China)
 (Thermo-hygrometer)
 (2:) 16 (20× 1)
 To 38- To/ 60 (38.5
 Tc/ 38.5
 39
 (Lawrence et al 1996;Susan et al.2006)
 (38.5)
 (Darren and Scott. 2006)
 (60)
 60
 (Farlim-(BF-197) Training- cup,China)
 (Susan.2005)
 (16-15)
 (Aquatics glass thermometer-Tropica,China)
 Digital thermometer-SDT-) (Eran et al.2004)
 (10A samsung, Korea
 Hct (radius artery) To
 Aldosterone (Sysmex k. 21-N, Japan) (Axilla)
 (Gamma counter-Radioimmunoassay/LKB Rack, Lawrence et) (Groins)
 Finland al.1996;Eran et al.2004;James et al.2005)
 Medlab (Referactometer, Portable, USA) Tc (12)
 10
 (Duffield et al., 2003; Darren and Scott, 2006)
 SPSS 12
 "Repeated measurements" (Bailey et al., 2007)
 / 15 200
 (Baseline) /
 Sandra (and Winfried.2007) (10~) 9~
 Scheffe 10 Antecubital vein fossa
 Scheffe
 Treadmill-)
 Seca-) (6310,USA
 (220.Germany
 :(HR)

.2

(2)

.(1)

/

(1)

.($\alpha < 0.05$)

Scheffe


.(1)

.(3)

4

.(1)

| | | | | |
|-------------|------------|-------------|------------|----|
| | | | | |
| 156.00±0.00 | 96.00±5.37 | 155.00±2.45 | 59.67±0.52 | C/ |
| 153.00±3.29 | 87.00±3.29 | 150.00±0.00 | 59.67±0.52 | W/ |
| 167.00±7.01 | 71.00±4.52 | 154.00±3.10 | 59.67±0.52 | I/ |



4

.1

.(2)

| | | | | | | |
|--------|---------|-------|---|-------|--|--|
| | | | | | | |
| | | 000 | 1 | 000 | | |
| | | 000 | 5 | 000 | | |
| 0.086 | 5.531 | 22.9 | 1 | 22.9 | | |
| | | 4.14 | 5 | 20.7 | | |
| 0.000* | 999.018 | 3051 | 1 | 3051 | | |
| | | 3.054 | 5 | 15.27 | | |
| 0.000* | 37.602 | 734 | 1 | 734 | | |
| | | 19.52 | 5 | 97.6 | | |

($\alpha < 0.05$)

*

Scheffe .(3)

| I | W | C | | |
|---------------|---------------|---------------|--------|----|
| 71.00 | 87.00 | 96.00 | | |
| 25.00* | 9.00 | | 96.00 | C/ |
| 16.00* | | | 87.00 | W/ |
| | | | 71.00 | I/ |
| I | W | C | | |
| 167.00 | 153.00 | 156.00 | | |
| 11.00* | 3.00 | | 156.00 | C/ |
| 14.00* | | | 153.00 | W/ |
| | | | 167.00 | I/ |

($\alpha < 0.05$)


*

(5) (3)
) (C/ W/) /
 ($\alpha < 0.05$) I/ (I/
 .(6) Scheffe W/) /
 (6) / (C/
 W/
 . C/
 :(T₀)
 .(4)
 / (4)
 .(7) .(2)
 / (7)
 .(3) .5

4

.(4)

| | | | | |
|------------|------------|------------|------------|----|
| | | | | |
| 38.63±0.21 | 37.48±0.17 | 37.98±0.15 | 36.17±0.05 | C/ |
| 38.27±0.20 | 36.97±0.12 | 37.58±0.13 | 36.18±0.03 | W/ |
| 37.55±0.10 | 36.63±0.03 | 38.02±0.15 | 36.23±0.03 | I/ |



4

.2

.(5)

| | | | | | | |
|--------|--------|--------|---|-------|--|--|
| | | | | | | |
| 0.125 | 3.636 | 0.016 | 1 | 0.016 | | |
| | | 0.0044 | 5 | 0.022 | | |
| 0.156* | 2.750 | 0.011 | 1 | 0.011 | | |
| | | 0.004 | 5 | 0.018 | | |
| 0.000* | 72.936 | 3.428 | 1 | 3.428 | | |
| | | 0.047 | 5 | 0.234 | | |
| 0.000* | 46.388 | 6.318 | 1 | 6.318 | | |
| | | 0.1362 | 5 | 0.681 | | |

($\alpha < 0.05$)

*

(Scheffe)


.(6)

| | | | | |
|--------------|--------------|--------------|-------|----|
| I | W | C | | |
| 38.02 | 37.58 | 37.98 | | |
| 0.04 | 0.40* | | 37.98 | C/ |
| 0.44* | | | 37.58 | W/ |
| | | | 38.02 | I/ |
| I | W | C | | |
| 36.63 | 36.97 | 37.48 | | |
| 0.85* | 0.51* | | 37.48 | C/ |
| 0.34* | | | 36.97 | W/ |
| | | | 36.63 | I/ |
| I | W | C | | |
| 37.55 | 38.27 | 38.63 | | |
| 1.08* | 0.36* | | 38.63 | C/ |
| 0.72* | | | 38.27 | W/ |
| | | | 37.55 | I/ |


($\alpha < 0.05$)

*


| I/ | W/ | C/ | Baseline | / |
|---------------|----------------|----------------|--------------|-------------|
| 45.00±1.55 | 45.83±2.14 | 46.17±2.48 | 43.00±0.89 | Hct |
| 55.00±1.55 | 54.17±2.14 | 53.83±2.48 | 57.00±0.89 | PV |
| 916.73±350.21 | 1285.70±405.10 | 1389.58±362.18 | 307.30±82.00 | Aldosterone |
| 1.009±0.003 | 1.015±0.003 | 1.018±0.003 | 1.007±0.003 | USG |



. 3



. 3



. 3

. 3- 3

:/

/(10)

/(10)

.8

(8)

Hct and PV

.Aldosterone and USG

.(4) .(9) Scheffe

(9)

Aldosterone and USG

.11

...

Scheffe
.12

(11)

/

.(8)

| | | | | | | |
|--------|--------|----------|---|----------|--|--------------|
| | | | | | | |
| 0.097 | 3.620 | 6.054 | 1 | 6.054 | | Hct |
| | | 1.6724 | 5 | 8.362 | | |
| 0.086 | 3.806 | 6.054 | 1 | 6.054 | | PV |
| | | 1.591 | 5 | 7.954 | | |
| 0.036* | 5.429 | 154867.6 | 1 | 154867.6 | | Aldos |
| | | 28526.96 | 5 | 142634.8 | | |
| 0.000* | 33.333 | 0.0004 | 1 | 0.0004 | | USG |
| | | 0.000012 | 5 | 0.00006 | | |

($\alpha < 0.05$)

*

Aldosterone and USG

Scheffe

.(9)


| I | W | C | | | |
|----------|----------|----------|---------|-----------|--------------------|
| 916.73 | 1285.70 | 1389.58 | | | |
| 472.85* | 103.88 | | 1389.58 | <i>c/</i> | Aldosterone |
| 368.97* | | | 1285.70 | <i>w/</i> | |
| | | | 916.73 | <i>i/</i> | |
| I | W | C | | | |
| 1.009 | 1.015 | 1.018 | | | |
| 0.009* | 0.003 | | 1.018 | <i>c/</i> | USG |
| 0.006* | | | 1.015 | <i>w/</i> | |
| | | | 1.009 | <i>i/</i> | |

($\alpha < 0.05$)

*

.(10)

| | | |
|------|-------|-----------|
| | | |
| 1.54 | 30.46 | <i>c/</i> |
| 1.78 | 34.75 | <i>w/</i> |
| 4.90 | 43.34 | <i>i/</i> |



.5

.(11)

| | | | | | | |
|--------|---------|---------|---|---------|--|--|
| | | | | | | |
| 0.000* | 166.495 | 734.514 | 1 | 734.514 | | |
| | | 4.41162 | 5 | 22.0581 | | |

($\alpha < 0.05$)

*

/

Scheffe

.(12)

| I | W | C | | |
|--------|-------|-------|-------|----|
| 43.34 | 34.75 | 30.46 | | |
| 12.88* | 4.29 | | 30.46 | C/ |
| 8.59* | | | 34.75 | W/ |
| | | | 43.34 | I/ |

($\alpha < 0.05$)

*

()

(12)

(Sandra and Winfried.2007)

(Hiroshi et al.2005)

HR .(Susan et al.2006)

)

"Heart rate (HR)"

(w/

HR

5.3

(/

156 153)

C/

167) I/

12.8

8.59

/

(/

HR
 . C and W
"Oral temperature (To)"
 To
 /
 "Endogenous"
 W HR
 "Exogenous"
 (C and I)
 To (1)
 C .
 .and I (Hiroshi et al.2005)
 HR
 60
 400
 Tre/ (Hiroshi et al., 2005) 50
 /
 (/ 71) I HR
 / (/ 87 96) C and W
 I and W
 .I /
 Conduction and "
 (Nag et al., 1998;
 ."Convection Stocks et al., 2004;Hiroshi et al.2005; Susan et al., 2006;
) Sandra and Winfried, 2007)
 HR (
 I To (Bailey et al., 2007)
 .C and W HR
 (Susan et al., 2006) 10
 Tre HR
 I Recovery
 .(Eran et al.2004) "Permeability" C and W (/ 71-154)
 / (/ 87-150 96-155)
 I and W /
 I .HR SV
 () CO and SV/)
 . 38.6 To (Marion.2002;Hiroshi et al.2005;Patricia and (HR
 I To Katie.2006;Marc et al.2006)
 (2 /) (Wilde. 1999) Sympathetic nerve

"Aldosterone hormone

I

concentration"

(Amid et (111.0 – 860.0 pmol/L)

al.2002)

.C C and W

-I

(Susan et al., 2006)

(916.33) ()

-

(Hiroshi et al., 2005)

(1389.58/1285.70) C and W

I To

BV

/

C and W

"and BP"

.(Susan et al., 2006; Sandra and Winfried,2007)

I

"Haematocrit (Hct) and

plasma volume (PV)"

/

(Stocks et al.2004)

/

Hct

Aldosterone

(Hoffbrand et al., 2006) (40-52%)

I

Baseline

Hct

BP

BV

PV

C and W

Renin

.(4) I ()

Renin-angiotensin aldosterone

Aldosterone

I

/

system (RAA)

Tortora and)

C and W

I

PV

.(Derrickson.2006

Aldosterone

I

.(4)

C

C and W

PV ()

I

.I

"Urine specific gravity (USG)"

(Maw et al., 1998)

PV

(Tortora and Derickson, (1.001-1.035)

Intracellular fluid (ICF) and PV

()

2006)

(Stocks et

.(36)

C and W

(1.009)

.ICF

al., 2004)

(1.018/1.015)

.I

Baseline

Extracellular fluid (ECF)

ICF

Herbert and Terry.1994;Susan, ECF

aldosterone

.(2005)

aldosterone

/

PV

(Susan et al.2006)

) ()

(Hiroshi et al.2005)

(

(Sandra and Winfried.2007)

()

Guyton and Hall.(2006)

USG

(Susan et al., 2006)

/

(43.34) %42.28

(30.46) (34.75) %14.08

.(6)

/

| |
|-------|
| |
| • |
| • |
| / () |

| |
|------|
| |
| Tc • |
| • |
| () |

(160+400)

/

(/)

50 12 (16-15)

(35-34)

).

.(

() .(560/ 10)

.%14.08 %42.28

() 2008-

"tub"

)

/

(5 / 1

- 36: 89-94.
- Maw, G. J., Mackenzi, I. L. and Tylor, N. A. S. 1998. Human body-fluid distribution during exercise in hot, temperate and cool environments. *Acta Physiol Scand*; 163, 297-304.
- Nag, P. K., Pradhan, C. K., Nag, A., Ashtekar, S. P. and Desai, H. 1998. Efficacy of a water-cooled garment for auxiliary body cooling in heat. *Ergonomics*; 41 (2): 179-187.
- Nielsen, Bodil and Nybo, Lars. 2003. Cerebral changes during exercise in the heat. *Sports Medicine*; 33 (1): 1-11.
- Patricia, A., Keresztes and Brick, Katie. 2006. Therapeutic hypothermia after cardiac arrest. *Dimens Crit Care Nurs*; 25 (2): 71-76.
- Quod, Marc J., Martin, David T. and Laursen, Paul B. 2006. Cooling athletes before competition in the heat. *Sports Med*; 36 (8): 671-682.
- Shirreffs, Susan M. 2005. The importance of good hydration for work and exercise performance. *Nutrition Reviews*; 63 (2): S14-S21.
- Smith, J. E. 2005. Cooling methods used in the treatment of exertional heat illness. *Br J Sports Med*; 39: 503-507.
- Stocks, J. M., Patterson, M. J., Hyde, A. B., Mittleman, K. D. and Tylor, N. A. S. 2004. Effects of immersion water temperature on whole-body fluid distribution in humans. *Acta Physiol Scand*; 182, 3-10.
- Told, Gabrielle, Bulter, Jane E., Tylor Janet L. and Gandevia, S. 2005. Hyperthermia: a failure of the motor cortex and the muscle. *J Physiol*; 563, 2, 621-631.
- Tortora, J., Bryan Gerard and Derickson. 2006. *Principle of Anatomy and Physiology*, 11th edition. Wiley, USA., 753, 1016, 1021.
- Ückert, Sandra and Winfried Joch. 2007. Effects of warm-up and precooling on endurance performance in the heat. *Br J Sports Med*; 41: 380-384.
- Wilde, A. D. 1999. The effect of cold water immersion on the nasal mucosa. *Clin Otolaryngol*; 24: 411-413.
- Yeargin, Susan W., Casa, Douglas J., Mclung, Joseph M., Chad, Knight J., Julie C., Healey, Joch P. Goss, William R. Harvard and George R. Hipp. 2006. Body cooling between two bouts of exercise in the heat enhances subsequent performance. *Journal of Strength and Conditioning Research*; 20 (2): 383-389.
- Abdelnour, Amid, Dahabreh, Nashat, Sahyoun, Zeina and Haddad, Jamie. 2002. *Labwise: guide to laboratory investigation*. Economic Press Co, 3rd edition, Jordan, 28.
- Amstrong, Lawrence E., Epstein, Yoram, Greenleaf, John E., Haymes, Emily M., Hubbard, Royer W., Roberts, William O. and Thompson, Paul D. 1996. American College of Sports Medicine, positioned stand: Heat and cold illnesses during distance running. *Med. Sci. Sports Exerc*. 28: i-x.
- Bailey, D. M., Erith, S. J., Griffin, P. J., Dowson, A., Brewer, D. S., Gant, N. and Williams, C. 2007. Influence of cold-water immersion on indices of muscle damage following prolonged intermittent shuttle running. *Journal of Sports Science*; 1-8, i first article.
- Devries, Herbert, A. and Housh, Terry J. 1994. *Physiology of exercise*, 5th edition. Brown and Benchmark Publishers, USA, 129.
- Duffield, R., Dawson, B., Bishop, D., Fitzsimons, M. and Lawrence, S. 2003. Effect of wearing an ice cooling jacket on repeat sprint performance in warm/ humid conditions. *Br J Sports Med*, 37, 164-169.
- James L., Glazer. 2005. Management of heatstroke and heat exhaustion. *American Family Physician Center*; 71 (11): 2133-2140.
- Guyton, C. Arthur and Hall John. 2006. *Textbook of medical physiology*. 11th edition. Elsevier Saunders, USA
- Haddad, Eran, Rav-Acha, Moshe, Heled, Yuval, Epstein, Yoram, and Daniel, S. 2004. Heat stroke: a review of cooling methods. *Sports Med*, 34 (8): 501-511.
- Hasegawa, Hiroshi, Takatori, Tadashi, Komura Takashi, and Yamasaki, Masahiro. 2005. Wearing a cooling jacket during exercise reduces thermal strain and improve endurance exercise performance in a warm environment. *Journal of Strength and Conditioning Research*; 19 (1): 122-128.
- Hoffbrand, A.V., Moss, P.A.H. and Pettit, J.E. 2006. *Essential Haematology*, 5th edition. Blackwell Publishing Ltd, UK. 16, 33-41.
- Johnson, Darren, L. and Mair Scott, D. 2006. *Clinical sports medicine*. Mosby and Elsevier Inc, USA, 47-55.
- Marino, F. E. 2002. Methods, advantages, and limitations of body cooling for exercise performance. *Br J Sports Med*;

The Effect of Cold Water Immersion and Cold Water Intake on some Physiological Responses and Endurance Time In a Hot Environment

*Mohammad F. Abu Mohammad and Sameera M. Orabi **

ABSTRACT

The aim of the present study was to examine the effect of cold water immersion and cold water intake on some physiological responses and endurance time in a hot environment. Using a random blind-design, 6 athletes participated in 3 trials (7 days apart). Athletes ran 50 minutes on a treadmill at moderate intensity in a laboratory (34-35°C) (session 1) before 12 min of the break in either cold water immersion/immersion trial, cold water intake/water trial or control trial. After the break, athletes performed an incremental running protocol on a treadmill until fatigue (session 2). Decreased oral temperature, aldosterone concentration, urine specific gravity and elevated heart rate were significantly lower postsession 2 in immersion trial. Oral temperature was significantly lower in water than control trial. There was no significant difference between trials in plasma volume. Endurance/running time was significantly longer in immersion trial than in the other trials ($\alpha < 0.05$). In conclusion, cold water immersion increased endurance time and enhanced physiological responses. The authors recommend using cold water immersion in a hot Olympic games in 2008 in Beijing.

Keywords: Hot Environment, Cold Water Immersion, Urine Specific Gravity.

*Faculty of Physical Education, University of Jordan, Amman, Jordan. Received on 17/1/2008 and Accepted for Publication on 22/6/2008.